Canaccord: 'Roche ups the ante with $150 genome and reusable chips (20x); may prove formidable vs. ILMN; HOLD'
Tweet Send to a Friend
Canaccord analyst Kyle Mikson reiterated a Hold rating and $150.00 price target on Illumina (NASDAQ: ILMN).The analyst comments "We reiterate ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
